We received a press release today from Genentech. Christine and I spoke to the Product Manager of Herceptin at San Francisco last weekend and he was very excited about this.
Trastuzumab (Herceptin®) is a drug used to treat breast cancer in women whose tumors contain the receptor for a protein called HER2. In some women, however, the drug stops working. Researchers are therefore seeking more effective drugs for this disease.
Trastuzumab-MCC-DM1 is an investigational drug that contains trastuzumab linked to a chemotherapy drug. When trastuzumab binds to the HER2 protein, it then releases the chemotherapy drug directly to the tumor cells. Trastuzumab-MCC-DM1 has caused cancer cells to die in laboratory studies, and has prevented or slowed the growth of breast cancer in animal studies.
http://www.clinicaltrials.gov/ct/sho...509769?order=1